Amgen's Aimovig Aims To Capture As Many Migraine Patients As Possible With $6,900 Price
Executive Summary
Amgen and Novartis won the first US FDA approval for a CGRP inhibitor in the prevention of migraine headaches. The companies aim to quickly capture a big share of what they estimate to be an 8m-patient market in the US with a $6,900 per year price tag.
You may also be interested in...
Migraine Market Update: CGRP Inhibitors Slowly Gain Ground
The market for novel preventive and acute treatments grew from three anti-CGRP antibodies at the start of 2020 to four biologics and two oral drugs against CGRP plus a small molecule 5-HT1F inhibitor.
Pricing Could Help Lundbeck's Vyepti In Slow-Growing CGRP Market
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.
Amgen's Murdo Gordon On Generating Sales Growth In A Challenging Commercial Year
Newer products are gaining ground, but not fast enough to replace sales as blockbuster products face competition. Scrip spoke with the company's global commercial head about the strategy going forward.